

Sun Pharma to pay \$550 million to settle patent infringement case

13 June 2013 | News | By BioSpectrum Bureau

Sun Pharma to pay \$550 million to settle patent infringement case



Sun Pharmaceutical Industries announced that it together with its subsidiaries, have settled an ongoing litigation regarding Sun Pharma subsidiary's generic pantoprazole. Under the terms of the litigation settlement between Sun Pharma, and Wyeth, (now a division of Pfizer) and Altana Pharma AG, (now known as Takeda GmbH), Sun Pharma will pay a lump-sum US \$550 million as a part of this settlement.

In 2005, Wyeth and Altana had filed a patent infringement suit against Sun Pharma after Sun Pharma filed its abbreviated new drug application for pantoprazole. Sun Pharma launched its generic pantoprazole in the US on January 30, 2008. In April 2010, a jury had determined that Altana's patent is not invalid. On June 3, 2013, the Court began a jury trial to assess the amount of past damages that Sun Pharma owed for infringing Altana's now expired patent. This settlement now culminates the ongoing litigation.

Sun Pharma can continue to sell its generic pantoprazole in the U.S.